Collagenase Clostridium histolyticum in Dupuytren's contracture: a guide to its use in the EU

详细信息    查看全文

• 作者：Kate McKeage ; Katherine Ann Lyseng-Williamson
• 刊名：Drugs & Therapy Perspectives
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：32
• 期：4
• 页码：131-137
• 全文大小：449 KB
• 参考文献：1.Azzopardi E, Boyce DE. Clostridium histolyticum collagenase in the treatment of Dupuytren’s contracture. Br J Hosp Med. 2012;73(8):432–6.CrossRef
  2.Schulze SM, Tursi JP. Postapproval clinical experience in the treatment of Dupuytren’s contracture with collagenase Clostridium histolyticum (CCH): the first 1000 days. Hand. 2014;9:447–58.CrossRef PubMed PubMedCentral
  3.Mafi R, Hindocha S, Khan W. Recent surgical and medical advances in the treatment of Dupuytren’s disease: a systematic review of the literature. Open Orthop J. 2012;6(Suppl 1):77–82.CrossRef
  4.Needle or open fasciotomy for Dupuytren’s contracture: a review of the comparative efficacy, safety, and cost-effectiveness—an update. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2013.
  5.Rodrigues JN, Becker GW, Ball C, et al. Surgery for Dupuytren’s contractures of the fingers. Cochrane Database Syst Rev. 2015;12:CD010143.PubMed
  6.Xiapex (Collagenase Clostridium histolyticum): summary of product characteristics. London: European Medicines Agency; 2015.
  7.Dhillon S. Collagenase Clostridium histolyticum: a review in Peyronie’s disease. Drugs. 2015;75(12):1405–12.CrossRef PubMed
  8.Hurst LC, Badalamente MA, Hentz VR, et al. Injectable collagenase Clostridium histolyticum for Dupuytren’s contracture. N Engl J Med. 2009;361(10):968–79.CrossRef PubMed
  9.Gilpin D, Coleman S, Hall S, et al. Injectable collagenase Clostridium histolyticum: a new nonsurgical treatment for Dupuytren’s disease. J Hand Surg Am. 2010;35(12):2027–38 (e1).CrossRef PubMed
  10.Witthaut J, Jones G, Skrepnik N, et al. Efficacy and safety of collagenase Clostridium histolyticum injection for Dupuytren contracture: short-term results from 2 open-label studies. J Hand Surg Am. 2013;38(1):2–11.CrossRef PubMed
  11.Peimer CA, Blazar P, Coleman S, et al. Dupuytren contracture recurrence following treatment with collagenase Clostridium histolyticum (CORDLESS [Collagenase Option for Reduction of Dupuytren Long-term Evaluation of Safety Study]): 5-year data. J Hand Surg Am. 2015;40:1597–605.CrossRef PubMed
  12.Badalamente MA, Hurst LC, Benhaim P, et al. Efficacy and safety of collagenase Clostridium histolyticum in the treatment of proximal interphalangeal joints in Dupuytren contracture: combined analysis of 4 phase 3 clinical trials. J Hand Surg Am. 2015;40:975–83.CrossRef PubMed
  13.Bainbridge C, Gerber RA, Szczypa PP, et al. Efficacy of collagenase in patients who did and did not have previous hand surgery for Dupuytren’s contracture. J Plast Surg Hand Surg. 2012;46:177–83.CrossRef PubMed PubMedCentral
  14.Warwick D, Arner M, Pajardi G, et al. Collagenase Clostridium histolyticum in patients with Dupuytren’s contracture: results from POINT X, an open-label study of clinical and patient-reported outcomes. J Hand Surg Eur. 2015;40(2):124–32.CrossRef
  15.Zhou C, Hovius SE, Slijper HP, et al. Collagenase Clostridium histolyticum versus limited fasciectomy for Dupuytren’s contracture: outcomes from a multicenter propensity score matched study. Plast Reconstr Surg. 2015;136(1):87–97.CrossRef PubMed
  16.Peimer CA, Wilbrand S, Gerber RA, et al. Safety and tolerability of collagenase Clostridium histolyticum and fasciectomy for Dupuytren’s contracture. J Hand Surg Eur. 2015;40(2):141–9.CrossRef
  17.Chen NC, Shauver MJ, Chung KC. Cost-effectiveness of open partial fasciectomy, needle aponeurotomy, and collagenase injection for Dupuytren contracture. J Hand Surg Am. 2011;36(1826–1834):e32.PubMed
  18.Baltzer H, Binhammer PA. Cost-effectiveness in the management of Dupuytren’s contracture: a Canadian cost-utility analysis of current and future management strategies. Bone Joint J. 2013;95-B:1094–100.CrossRef PubMed
  19.De Salas-Cansado M, Cuadros M, Del Cerro M, et al. Budget impact analysis in Spanish patients with Dupuytren’s contracture: fasciectomy vs. collagenase Clostridium histolyticum. Chir Main. 2013;32(2):68–73.CrossRef PubMed
  20.Mehta S, Belcher HJ. A single-centre cost comparison analysis of collagenase injection versus surgical fasciectomy for Dupuytren’s contracture of the hand. J Plast Reconstr Aesthet Surg. 2014;67(3):368–72.CrossRef PubMed
  21.Sanjuan Cerveró R, Franco Ferrando N, Poquet Jornet J. Use of resources and costs associated with the treatment of Dupuytren’s contracture at an orthopedics and traumatology surgery department in Denia (Spain): collagenase Clostridium histolyticum versus subtotal fasciectomy. BMC Musculoskelet Disord. 2013;14:293.
  22.Atroshi I, Strandberg E, Lauritzson A, et al. Costs for collagenase injections compared with fasciectomy in the treatment of Dupuytren’s contracture: a retrospective cohort study. BMJ Open. 2014;4(1):e004166.CrossRef PubMed PubMedCentral
  23.Povlsen B, Povlsen SD. What is the better treatment for single digit Dupuytren’s contracture: surgical release or collagenase Clostridium histolyticum (Xiapex) injection? Hand Surg. 2014;19(3):389–92.CrossRef PubMed
  24.Nydick JA, Olliff BW, Garcia MJ, et al. A comparison of percutaneous needle fasciotomy and collagenase injection for Dupuytren disease. J Hand Surg Am. 2013;38:2377–80.CrossRef PubMed
  25.Coleman S, Gilpin D, Kaplan FT, et al. Efficacy and safety of concurrent collagenase Clostridium histolyticum injections for multiple Dupuytren contractures. J Hand Surg Am. 2014;39:57–64.CrossRef PubMed
  26.Gaston RG, Larsen SE, Pess GM, et al. The efficacy and safety of concurrent collagenase Clostridium histolyticum injections for 2 Dupuytren contractures in the same hand: a prospective, multicenter study. J Hand Surg Am. 2015;40:1963–71.CrossRef PubMed
  
• 作者单位：Kate McKeage (1)
  Katherine Ann Lyseng-Williamson (1)
  
  1. Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand
  
• 刊物主题：Pharmacy; Pharmacotherapy;
• 出版者：Springer International Publishing
• ISSN：1179-1977

文摘

Collagenase Clostridium histolyticum (CCH; Xiapex®) is an injectable enzymatic collagenase approved for the treatment of Dupuytren’s contracture (DC). In two double-blind studies, up to three injections (mean of 1.5) of CCH per cord at monthly intervals were significantly more effective than placebo in reducing contractures, achieving clinical success in 64 % of treated joints affected by DC. CCH is generally well tolerated, with most adverse effects being local, transient injection-site reactions, such as oedema, pain and bruising. There is some evidence suggesting that CCH is associated with fewer major complications than open fasciectomy among selected patients. Estimated costs associated with CCH are generally lower than those associated with fasciectomy, but cost-effectiveness based on accepted willingness-to-pay thresholds is dependent on injection price.